Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report
- 10 June 2024
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 205 (3) , 1208-1211
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman diseaseInternational Journal of Hematology, 2024
- Idiopathic multicentric Castleman disease (iMCD)‐idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD‐not otherwise specified with different clinical features and better survivalBritish Journal of Haematology, 2024
- Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise SpecifiedChest, 2023
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman diseaseNature Communications, 2022
- Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case reportAnnals of Hematology, 2022
- A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCDLeukemia & Lymphoma, 2022
- Orelabrutinib: First ApprovalDrugs, 2021
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman diseaseJournal of Clinical Investigation, 2019
- Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman diseaseAmerican Journal of Hematology, 2018
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017